S
43.48
-0.79 (-1.78%)
| Penutupan Terdahulu | 44.27 |
| Buka | 43.04 |
| Jumlah Dagangan | 1,409,299 |
| Purata Dagangan (3B) | 1,036,905 |
| Modal Pasaran | 4,435,283,968 |
| Harga / Jualan (P/S) | 13.14 |
| Harga / Buku (P/B) | 18.40 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Mar 2026 |
| EPS Cair (TTM) | -2.55 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.22% |
| Nisbah Semasa (MRQ) | 10.25 |
| Aliran Tunai Operasi (OCF TTM) | -229.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -134.32 M |
| Pulangan Atas Aset (ROA TTM) | -50.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -106.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Scholar Rock Holding Corporatio | Menaik | Menaik |
AISkor Stockmoo
-1.0
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.35% |
| % Dimiliki oleh Institusi | 118.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (BMO Capital, 60.99%) | Beli |
| Median | 58.00 (33.40%) | |
| Rendah | 53.00 (Barclays, 21.90%) | Beli |
| Purata | 58.86 (35.37%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 43.59 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BMO Capital | 04 Mar 2026 | 70.00 (60.99%) | Beli | 43.48 |
| Barclays | 04 Mar 2026 | 53.00 (21.90%) | Beli | 43.48 |
| 17 Dec 2025 | 52.00 (19.60%) | Beli | 44.01 | |
| Citigroup | 04 Mar 2026 | 58.00 (33.39%) | Beli | 43.48 |
| 09 Jan 2026 | 55.00 (26.49%) | Beli | 42.18 | |
| Piper Sandler | 04 Mar 2026 | 58.00 (33.39%) | Beli | 43.48 |
| Truist Securities | 04 Mar 2026 | 55.00 (26.49%) | Beli | 43.48 |
| HC Wainwright & Co. | 03 Mar 2026 | 58.00 (33.39%) | Beli | 43.48 |
| 26 Jan 2026 | 58.00 (33.39%) | Beli | 44.89 | |
| UBS | 07 Jan 2026 | 60.00 (37.99%) | Beli | 44.23 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| QATANANI MO | - | 47.01 | -8,484 | -398,833 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,484 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -398,833 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 47.01 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| QATANANI MO | Pegawai | 23 Feb 2026 | Jual automatik (-) | 8,484 | 47.01 | 398,833 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Pengumuman | Scholar Rock Highlights 2026 Strategic Priorities |
| 05 Jan 2026 | Pengumuman | Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 13 Dec 2025 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |